Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease
Background. Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still’s disease (AOSD). However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case series. Pa...
Saved in:
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2020/8054961 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!